XML 22 R9.htm IDEA: XBRL DOCUMENT v3.21.2

Certain Balance Sheet Accounts

6 Months Ended

Jun. 30, 2021

Certain Balance Sheet Accounts

Certain Balance Sheet Accounts

Note 4—Certain Balance Sheet Accounts

Accounts Receivable, net

Accounts receivable, net consist of the following:

​

​	​	​	​	​	​	​
​	​	June 30,		​	December 31,
​		2021			2020
​	​	(In thousands)
Trade receivables, net	​	$	31,418	​	$	3,771
Sublease and other receivables	​		420	​		70
Total accounts receivables, net	​	$	31,838	​	$	3,841

​

Trade receivables are net of product return and chargeback allowances of $1.9 million and $1.2 million as of June 30, 2021 and December 31, 2020, respectively.

Inventory

Inventory consists of the following:

​

​	​	​	​	​	​	​
​	​	June 30,		​	December 31,
​		2021			2020
​	​	(In thousands)
Raw materials		$	361		$	109
Work-in-progress	​		230	​		462
Finished goods	​		387	​		784
Total inventory		$	978		$	1,355

​

Property and Equipment, Net

Property and equipment, net consists of the following:

​

​	​	​	​	​	​	​
​		June 30,			December 31,
​	​	2021		​	2020
​	​	(In thousands)
Finance leases	​	$	5,690	​	$	5,690
Laboratory equipment	​		2,998	​		2,898
Computer equipment	​		985	​		985
Office equipment and furniture	​		625	​		625
Total cost	​		10,298	​		10,198
Less accumulated depreciation and amortization	​		(8,391)	​		(7,647)
Total property and equipment, net	​	$	1,907	​	$	2,551

​

For the three months ended June 30, 2021 and 2020, depreciation and amortization expenses were $0.4 million for each of the two periods. For the six months ended June 30, 2021 and 2020, depreciation and amortization expenses were $0.7 million and $0.8 million, respectively.

Accrued Expenses

Accrued expenses consist of the following:

​

​	​	​	​	​	​	​
​		June 30,			December 31,
​	​	2021		​	2020
​	​	(In thousands)
Sales rebates, fees and discounts	​	$	7,572	​	$	3,326
Contract research and development	​	​	5,576	​		7,952
Consulting and professional fees	​		4,770	​	​	5,393
Interest payable	​		5,173	​		5,205
Employee compensation	​		7,872	​		3,948
Clinical trials	​		1,874	​		2,121
Other accrued expenses	​		484	​		810
Total accrued expenses	​	$	33,321	​	$	28,755

​

X

- References

No definition available.

+ Details

Name:	us-gaap_BalanceSheetRelatedDisclosuresAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-URI http://asc.fasb.org/topic&trid=2122208

+ Details

Name:	us-gaap_SupplementalBalanceSheetDisclosuresTextBlock
Namespace Prefix:	us-gaap_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration